| Theme | Renal Osteodystrophy, Up-To-Date | |
|---|---|---|
| Title | Novel therapeutic strategies for ROD | |
| Publish Date | 2006/01 | |
| Author | Hiroaki Ogata | Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| Author | Chiaki Maeda | Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| Author | Kanji Shishido | Department of Internal Medicine, Kawasaki Clinic |
| Author | Eriko Kinugasa | Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| [ Summary ] | Renal osteodystrophy (ROD) leads to not only bone disorders, but also high morbidity and mortality of cardiovascular disease in patients receiving long-term dialysis therapy. It has been shown that conventional treatment, including calcium-based phosphate binder and active vitamin D ana logues, could not attain the novel therapeutic targets for ROD management, which have been proposed in the K/DOQI guidelines. Currently, in Japan, sevelamer hydrochloride is clinically available, as well as new vitamin D analogues. In this article, we review some new therapeutic strategies for the treatment of ROD. | |